Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
NCT07658105Phase 2Active, not recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of apalolithovolrelimab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jun 2026; status: active, not recruiting.
02
Drugs
apalolithovolrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07658105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07658105.